Dr. Morgan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
777 PRB
Nashville, TN 37232Phone+1 615-936-8422
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1994 - 1998
Yale-New Haven Medical CenterResidency, Internal Medicine, 1990 - 1993
Vanderbilt University School of MedicineClass of 1990
Certifications & Licensure
CA State Medical License 1994 - Present
TN State Medical License 1997 - 2026
AL State Medical License 2020 - 2020
CT State Medical License 1993 - 1994
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2014 Mar 13
Publications & Presentations
PubMed
- Progressive multifocal leukoencephalopathy after CAR-T cell therapy.Michael Montoya, Hannah J Harmsen, Brittney Baer, Nancy Long, Amy Messimore
Bone Marrow Transplantation. 2024-12-01 - 10 citationsThe iRregimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study.Radhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, Jia Ruan, Kirit M Ardeshna
Eclinicalmedicine. 2023-02-01 - 39 citationsNCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022.Richard T Hoppe, Ranjana H Advani, Weiyun Z Ai, Richard F Ambinder, Philippe Armand
Journal of the National Comprehensive Cancer Network. 2022-04-01
Abstracts/Posters
- Combination of Nivolumab, Lenalidomide and Rituximab in Relapsed/Refractory Non-Germinal Center Diffuse Large B Cell Lymphoma: Results from a Dose-Escalation CohortDavid Morgan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Phase 2 Results of the iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell_like (Non-GCB) Diffus...David Morgan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
Patient Receives Antibodies Discovered at Vanderbilt to Prevent COVID-19December 23rd, 2021- Lovelace Upgrades Staff MasksJuly 17th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
